Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...

Dysrhythmias VII: Nursing Management of Dysrhythmias

Dysrhythmias VII: Nursing Management of Dysrhythmias

Nursing management of dysrhythmias involves the following:AssessmentSubjective Assessment:The initial step involves gathering patient-reported symptoms such as dizziness, palpitations, and chest discomfort. It is crucial to collect a detailed history, including previous heart conditions, current medication use, and lifestyle factors like caffeine and alcohol consumption.Objective Assessment:This involves observing clinical signs such as jugular venous distention, cool and pale skin, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Gestational breast cancer: distinctive molecular and clinico-epidemiological features.

Journal of mammary gland biology and neoplasia·2024

Same author

Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015-04 (PANGEA-Breast) study.

BMC cancer·2022

Same author

Regulation of cardiac ion channels by transcription factors: Looking for new opportunities of druggable targets for the treatment of arrhythmias.

Biochemical pharmacology·2022

Same author

Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL.

Annals of oncology : official journal of the European Society for Medical Oncology·2021

Same author

Clinical outcome and subchondral bone edema presence at two-year follow-up after high density autologous chondrocyte implantation treatment in the knee.

Revista espanola de cirugia ortopedica y traumatologia (English ed.)·2019

Same author

[New calcium channel blockers for the treatment of hypertension].

Hipertension y riesgo vascular·2018

Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023

Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 3, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Dronedarone.

J Tamargo¹, A López-Farré, R Caballero

¹Department of Pharmacology, Universidad Complutense, Madrid, Spain. jtamargo@med.ucm.es

Drugs of Today (Barcelona, Spain : 1998)

|March 25, 2011

Summary

This summary is machine-generated.

Dronedarone effectively controls heart rate and rhythm in atrial fibrillation (AF) patients. It offers a better safety profile than amiodarone, reducing hospitalizations without significant thyroid, lung, or nerve toxicity.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

Related Experiment Videos

Last Updated: Jun 3, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

Area of Science:

Cardiology
Pharmacology

Background:

Atrial fibrillation (AF) is a common arrhythmia linked to significant illness and death.
Dronedarone, a benzofuran derivative, is structurally similar to amiodarone but lacks iodine, reducing lipophilicity and tissue accumulation.
It exhibits properties of all four Vaughan Williams antiarrhythmic drug classes by blocking cardiac ion channels and beta-adrenoceptors.

Purpose of the Study:

To review the electrophysiological and pharmacological characteristics of dronedarone.
To evaluate the efficacy and safety of dronedarone in managing atrial fibrillation.
To compare dronedarone's profile with amiodarone.

Main Methods:

Analysis of clinical trial data on dronedarone's efficacy in rhythm and rate control.
Review of studies assessing dronedarone's safety profile, including organ-specific toxicities.
Comparison of dronedarone's effectiveness and safety against placebo and amiodarone.

Main Results:

Dronedarone demonstrated effectiveness in maintaining sinus rhythm and controlling ventricular rate in AF patients.
The ATHENA trial showed dronedarone reduced cardiovascular hospitalizations or death in nonpermanent AF.
Dronedarone exhibited a superior safety profile compared to amiodarone, notably lacking thyroid, pulmonary, and neurological toxicity.

Conclusions:

Dronedarone is an effective antiarrhythmic agent for both rhythm and rate control in atrial fibrillation.
Its favorable safety profile, particularly the absence of amiodarone-related toxicities, makes it a valuable therapeutic option.
Dronedarone offers a reduced risk of cardiovascular hospitalizations in specific AF patient populations.